Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Interest Expenses (2016 - 2025)

Adma Biologics' Interest Expenses history spans 13 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 43.52% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $7.1 million, down 48.96%, while the annual FY2025 figure was $7.1 million, 48.96% down from the prior year.
  • Interest Expenses reached $1.6 million in Q4 2025 per ADMA's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $6.4 million in Q3 2023 to a low of $1.6 million in Q4 2025.
  • Average Interest Expenses over 5 years is $3.9 million, with a median of $3.4 million recorded in 2022.
  • Peak YoY movement for Interest Expenses: soared 50860.29% in 2021, then crashed 53.68% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $3.3 million in 2021, then soared by 73.0% to $5.7 million in 2022, then grew by 8.34% to $6.2 million in 2023, then plummeted by 53.68% to $2.9 million in 2024, then tumbled by 43.52% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Interest Expenses are $1.6 million (Q4 2025), $1.7 million (Q3 2025), and $1.8 million (Q2 2025).